2.50
Hdl Handle:
http://hdl.handle.net/10033/288595
Title:
Comorbidities in ADHD children treated with methylphenidate: a database study.
Authors:
Kraut, Angela A; Langner, Ingo; Lindemann, Christina; Banaschewski, Tobias; Petermann, Ulrike; Petermann, Franz; Mikolajczyk, Rafael T ( 0000-0003-1271-7204 ) ; Garbe, Edeltraut
Abstract:
Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users compared to a control group without ADHD and ADHD medication.
Affiliation:
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Citation:
Comorbidities in ADHD children treated with methylphenidate: a database study. 2013, 13:11 BMC Psychiatry
Journal:
BMC psychiatry
Issue Date:
2013
URI:
http://hdl.handle.net/10033/288595
DOI:
10.1186/1471-244X-13-11
PubMed ID:
23294623
Type:
Article
Language:
en
ISSN:
1471-244X
Appears in Collections:
Publications of the AG (ESME)

Full metadata record

DC FieldValue Language
dc.contributor.authorKraut, Angela Aen_GB
dc.contributor.authorLangner, Ingoen_GB
dc.contributor.authorLindemann, Christinaen_GB
dc.contributor.authorBanaschewski, Tobiasen_GB
dc.contributor.authorPetermann, Ulrikeen_GB
dc.contributor.authorPetermann, Franzen_GB
dc.contributor.authorMikolajczyk, Rafael Ten_GB
dc.contributor.authorGarbe, Edeltrauten_GB
dc.date.accessioned2013-05-07T12:45:54Zen
dc.date.available2013-05-07T12:45:54Zen
dc.date.issued2013en
dc.identifier.citationComorbidities in ADHD children treated with methylphenidate: a database study. 2013, 13:11 BMC Psychiatryen_GB
dc.identifier.issn1471-244Xen
dc.identifier.pmid23294623en
dc.identifier.doi10.1186/1471-244X-13-11en
dc.identifier.urihttp://hdl.handle.net/10033/288595en
dc.description.abstractMethylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro- and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of comorbid conditions related to these contraindications in new MPH users compared to a control group without ADHD and ADHD medication.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to BMC psychiatryen_GB
dc.titleComorbidities in ADHD children treated with methylphenidate: a database study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.en_GB
dc.identifier.journalBMC psychiatryen_GB

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.